|

New CSF Biomarkers for Alzheimer's Disease

RECRUITINGSponsored by Central Hospital, Nancy, France
Actively Recruiting
SponsorCentral Hospital, Nancy, France
Started2013-07-12
Est. completion2050-12-31
Eligibility
Healthy vol.Accepted
View on ClinicalTrials.gov →

NCT03621839

Summary

Today, the Alzheimer's disease (AD) diagnosis is founded not only on clinical criteria but also on complementary examinations to confirm a physiopathological process of AD. In complex cases, lumbar punction could be necessary in order to measure Aβ peptides and Total and phosphorylated Tau but new biomarkers could be useful. The main objective of this project is to conserve these cerebrospinal fluids, collected in usual practice in order to validate new biomarkers for diagnosis, prognosis or therapeutic following of Alzheimer's disease and other dementia.

Eligibility

Healthy volunteers accepted
Inclusion Criteria:

* Lumbar punction collected in usual practice in the context of dementia diagnosis

Exclusion Criteria:

* Absence of consent

Conditions4

Alzheimer DiseaseAlzheimer's DiseaseDementiaNeurodegenerative Diseases

Browse More Trials

Alzheimer's Disease trials

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.